PT  - JOURNAL ARTICLE
AU  - Yubin Miao
AU  - Thomas P. Quinn
TI  - Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
AID  - 10.2967/jnumed.120.243840
DP  - 2021 Mar 01
TA  - Journal of Nuclear Medicine
PG  - 313--318
VI  - 62
IP  - 3
4099  - http://jnm.snmjournals.org/content/62/3/313.short
4100  - http://jnm.snmjournals.org/content/62/3/313.full
SO  - J Nucl Med2021 Mar 01; 62
AB  - Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin α4β1) are 2 attractive molecular targets for developing peptide radiopharmaceuticals for melanoma imaging and therapy. MC1R- and VLA-4–targeting peptides and peptide-conjugated Cornell prime dots (C′ dots) can serve as delivery vehicles to target both diagnostic and therapeutic radionuclides to melanoma cells for imaging and therapy. This review highlights the advances of MC1R- and VLA-4–targeted radiolabeled peptides and peptide-conjugated C′ dots for melanoma imaging and therapy. The promising preclinical and clinical results of these new peptide radiopharmaceuticals present an optimistic outlook for clinical translation into receptor-targeting melanoma imaging and radionuclide therapy in the future.